- Included category
- Clinical and behavioral-support membership
- Not included
- GLP-1 medication cost
- Term
- Six or twelve months for the advertised introduction
The product being purchased is care access
Med+ is a membership supporting clinical assessment and ongoing care. WeightWatchers describes approved-medication options, but joining does not mean every member receives the same drug or formulation. This review treats it as a care product, with the medication kept as a separate line in the comparison.[source]
That matters on a site comparing tirzepatide and semaglutide. A decision between medicines requires an assessment of the person and the actual approved product. A decision between care memberships concerns access, support and cost. Combining those decisions into one headline price obscures both.
Read the commitment after the first payment
The $25 first-month offer is tied to a six- or twelve-month plan. The published later rates are $84 and $74 per month respectively, with GLP-1 medication excluded. The term is important: paying monthly within a longer commitment is not necessarily the same as a cancel-any-month service.[source]
Before joining, obtain the current cancellation terms and the likely medication cost under the intended insurance or cash-pay route. Ask what charges apply if treatment is not prescribed or coverage is denied. The membership page’s description of insurance help does not guarantee either decision.
Translate the feature list into access questions
WeightWatchers describes a care team, clinical check-ins, nutrition support, an app and a companion behavioral program. Ask which services are individual appointments, group formats or digital content, and how to reach a clinician about a medication question. Availability of an app is not the same as an immediate medical response.[source]
We have not tested the appointments, insurance process or app. The review evaluates the published care model. A reader who primarily wants structured behavioral support may weigh that model differently from someone already receiving those services through an existing clinician.
Member averages are not a medicine trial
The page’s engagement analysis uses self-reported member outcomes and is explicitly nonrandomized. It should not be used to claim that Med+ changes the comparative efficacy of tirzepatide and semaglutide or that a particular customer will match the reported average.[source]
Use the evidence guide to examine that distinction, then compare the full membership-plus-medicine cost with other pathways. The program’s value depends on the care and support actually needed, as well as an appropriate prescription.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- WeightWatchers: Med+ membership, medication access and outcome footnotesMembership excludes GLP-1 medication. Behavioral-program comparison is an internal, nonrandomized analysis of self-reported weights. · Checked October 10, 2026